by

Could Your Dog Meds End Malaria or Zika Infections?

Mosquito photo

Will the sun soon be setting on dangerous mosquito populations?

Could that once-monthly beef-flavored pill you give your dog to kill fleas and ticks save thousands of human lives in Zika virus- and malaria-infected areas of the world?

That’s the hypothesis examined in a 2018 publication “Repurposing isoxazoline veterinary drugs for control of vector-borne human diseases”, published by Miglianico, et al., in PNAS.

Vector-Borne Diseases Under Siege
Mosquito-transmitted diseases, such as malaria and Zika virus, and sand fly-transmitted leishmaniasis are major causes of mortality in sub-tropical regions. Although with a lower mortality incidence, mosquito-borne West Nile virus has spread in temperate regions such as Europe and the United States. Continue reading →

by

Shaping the Future by Investing in Science

“Today is certainly a great day for Promega R&D, but it is also a great day for science.”

Picture of people gathered

Community members and Promega employees gather for the ground breaking celebration for a new R&D facility.

Gary Tarpley, director of Research and Development at Promega closed his remarks for the ground breaking of the new Promega Research and Development Center in Fitchburg, WI, with those words.

With the ground breaking on this new R&D facility, Promega makes a $190 million, long-term investment in science.

But why invest in science?
Continue reading →

by

Beneath the Writing: Non-Invasive DNA Sampling from Modern and Historic Writing Surfaces

We can learn a lot about the past and its people from the written records of the time. What people write and how they write it can gives us glimpses into historical events, interpersonal relationships, social standing and even social and cultural norms. From paper to papyrus to clay tablets, the surface that holds the writing can tell us things that the words cannot.

For plant-based writing surfaces, the quality of the surface or even the technique used to make it can give historians and archeologists insight into the people who used them. What more could we learn if we knew what plant, or plants, were used in the production of ancient writing material? Continue reading →

by

Tetanus Neurotoxin: Potential Mechanism for Drug Delivery

Tetanus neurotoxin (TeNT), produced by Clostridium tetani, is one of the most potent neurotoxins in humans. TeNT causes tetanus, which is characterized by painful muscular contractions and spasms as well as seizure. TeNT is composed of a light chain and a heavy chain (TTH). The toxic properties of TeNT reside in the toxin light chain (L), but like complete TeNT, the TeNT heavy chain (TTH) and the C-terminal domain (TTC) alone can bind and enter into neurons.

Based on these properties, a recent publication (1) considered that TTC could be a promising vehicle to deliver drug cargos to neurons. To explore this possibility, they engineered fusion proteins containing various TeNT fragments. They chose B-cell leukemia/lymphoma 2 protein (Bcl-2) as a partner protein, because Bcl-2 is one of the most potent anti-apoptotic proteins and has an appropriate size (26kDa) to act as a fusion partner.

They tested these fusion proteins in both cell-based and cell-free protein expression systems to determine whether the purified fusion products retained both anti-apoptotic and neuronal migration properties. One construct (Bcl2-hTTC) exhibited neuronal binding and prevented cell death of neuronal PC12 cells induced by serum and NGF deprivation, as evidenced by the inhibition of cytochrome C release from the mitochondria. For in vivo assays, Bcl2-hTTC was injected into the tongues of mice and was seen to selectively migrate to hypoglossal nuclei mouse brain stems.

  1. Watanbe, Y. et. al. (2018) Tetanus toxin fragments and Bcl-2 fusion proteins : cytoprotection and retrograde axonal migration. BMC Biotechnology 18, 39.
by

All You Need is a Tether: Improving Repair Efficiency for CRISPR-Cas9 Gene Editing

Ribonucleoprotein complex with Cas9, guide RNA and donor ssDNA. Copyright Promega Corporation.

With the advent of genome editing using CRISPR-Cas9, researchers have been excited by the possibilities of precisely placed edits in cellular DNA. Any double-stranded break in DNA like that induced by CRISPR-Cas9 is repaired by one of two pathways: Non-homologous end joining (NHEJ) or homology-directed repair (HDR). Using the NHEJ pathway results in short insertions or deletions (indels) at the break site, so the HDR pathway is preferred. However, the low efficiency of HDR recombination to insert exogenous sequences into the genome hampers its use. There have been many attempts at boosting HDR frequency, but the methods compromise cell growth and behave differently when used with various cell types and gene targets. The strategy employed by the authors of an article in Communications Biology tethered the DNA donor template to Cas9 complexed with the ribonucleoprotein and guide RNA, increasing the local concentration of the donor template at the break site and enhancing homology-directed repair. Continue reading →

by

“GenEthics” – The Implications of Genomic Data

I majored in genetics because I love Punnett Squares. Don’t get me wrong, I was fascinated by the groundbreaking research going on in fields like oncology and agriculture, but there was something about the simple and logical nature of calculating inheritance patterns that really drew me in. At the time when I confusingly wandered into my advisor’s office to make this life changing academic decision, I had no idea that this degree would help me see the more complicated, “gray area”, of science, changing the way that I look at the world today.

What is “GenEthics” ?

As I’m sure you’ve already guessed, “GenEthics” is the intersection between the fields of genetics and ethics. A broad term involving questions related to the implications of a variety of different topics in genetic research; “GenEthics” covers everything from the modification of stem cells, to gene therapy and GMOs. Since this term encompasses such a large array of topics, I’m going to focus on some of the ethical questions related to your genome.

Genomic data and its applications

If you’ve ever heard of 23andMe or Ancestry.com then you’ve already had an introduction to genomic data. These direct-to-consumer genetic testing companies are a result of advancements in technology that have made the genotyping process relatively cheap and quick. When you submit a sample, they send it to a lab, extract the DNA, and test it for various markers. What’s returned to you is a report of what markers (alleles) you do and don’t have. These reports can tell you everything from what percent German you are, to your status for any of the many alleles of several genes that may increase risk for Alzheimer’s disease. Genomic data has affected a variety of fields; knowledge of the genome has allowed us to catch famous criminals like the Golden State Killer and has provided us with diagnostic markers for serious diseases. But even with all the good that genomic data has done and will do, there is a “gray area” where many questions regarding safety, equality, and privacy lie.

Safety – Should everyone have their genomes sequenced?

Some believe this is the future of healthcare, that everyone will have their genomes sequenced at birth and put into a national database. This would have amazing implications in the research world; access to endless data, and the ability to form conclusions about everything from human disease to intelligence.

This question also brings up a plethora of others, some pertaining to identity safety. In particular, what if this fictitious database is hacked? There have already been smaller-scale database breaches, the most recent being on the MyHeritage website. These breaches are potentially dangerous; the entirety of your personal health information is housed in your genome. With proper scientific guidance, hackers could infer your: gender, ethnicity, disease status, etc. DNA is not like a credit card, there is no way to obtain a new set of genes.

Equality – How do we ensure that everyone benefits from the advancements that genomic data has to offer?

There are many studies being done with the goal of eradicating cancer using precision medicine. This involves finding common tumor-causing variants in patients’ DNA sequences, and treating them based on their genes. These types of studies have the potential to contribute greatly to the field of personalized medicine, but caution needs to be taken to ensure that multiple populations are represented in the study. Ethnic groups have evolved on separate continents and their genetic sequences contain different variations, one set of conclusions about a disease might not apply to all populations.

Privacy: Who has a right to your genetic information?

The Genetic Nondiscrimination Act (GINA) was passed in 2008 to prevent your genetic test results from affecting your qualification for health insurance, or employment prospects. However, this is but a scratch on the surface of possible genomics-related legal issues; the ownership of a DNA sequence is a complete question mark at this time. There are no laws regarding an organization or family members’ right to an individual’s sequence.

Genomic data has the ability to save lives and prevent devastating disease, but it also can cause disputes within families, and between organizations and individuals. The question of DNA ownership brings up many others: if you test positive for a condition, should you inform other at risk family members? Do you have sole claim on your DNA when you have family members that share most of your sequence? When you submit your DNA to an organization what ownership rights do they have?

The Future…

We have come a long way since completion of the Human Genome Project back in 2003, and we will continue to make amazing advances thanks to the field of genetics. The questions I have posed are just a few that lie in the “gray area” we will be venturing into in the future. These questions may seem as if they are just for researchers, doctors, and lawyers, but they really are for everyone. The social and ethical implications of science affect us all; it’s important that we all join the conversation!

by

High-Throughput Drug Screening Using 3D Cell Cultures

For a long time, the drug industry has relied on flat 2D cell cultures grown on a plate to screen for potential drugs. However, 2D models do not accurately reflect the native environment of cells in vivo. 3D cell cultures, on the other hand, better represent the numerous cell-cell and cell-matrix interactions and hypoxic conditions that have a profound effect on the behavior of cells. In a 2018 study published in Oncogene, Kota et al. developed a high-throughput 3D spheroid-based screening assay to identify drug candidates that target RAS proteins.

RAS proteins are GTPases that transmit extracellular signals into cellular signaling pathways, which could activate cell proliferation, differentiation and survival mechanisms. Oncogene mutation in the three human RAS genes (HRAS, NRAS and KRAS) are found in 30% of all cancers, making RAS proteins the most common oncogene. In fact, mutations in KRAS are found in >90% of pancreatic cancers. Despite the prevalence of RAS mutations, targeting RAS proteins with drugs is extremely challenging due to the complex nature of the protein.

The authors in this study wanted to test a new approach using a 3D spheroid-based screening assay to find drugs that target RAS proteins. They first harvested 2D monolayer cultures of pancreatic epithelial tumor cells that express either wild-type KRAS or mutant oncogenic KRAS, and tested their ability to form 3D spheroids. They confirmed spheroid growth using the CellTiter-Glo® 3D Cell Viability Assay with linearity of detection in the range of 1,000–10,000 cells seeded.

The 3D spheroids were then treated with a library of 1,280 known drugs. From the high-throughput screen, they identified one compound with the greatest selective inhibition against oncogenic KRAS. The compound is called Proscillaridin A, a cardiac glycoside that is known for treating congestive heart failure and cardiac arrhythmia. In 3D spheroids, Proscillardin A inhibited oncogenic KRAS at a >90% inhibition rate, with <10% inhibition of wild-type KRAS. In 2D cultures, however, there was no selective inhibition of oncogenic KRAS (inhibition rates for both oncogenic and wild-type KRAS were about 50%). This means that Proscillaridin A would not have been identified as a candidate if the screen was done using only 2D cultures.

Next, the authors wanted to determine how Proscillaridin A impacts tumor cell viability. Could it induce apoptosis in tumor cells? To test this, they used the RealTime-Glo™ Annexin V Apoptosis Assay. This bioluminescent assay is able to detect apoptosis in real time, based on the exposure of phosphatidylserine on the outer leaflet of the cell membrane when apoptosis occurs. Using this assay, they found that Proscillaridin A induced apoptosis at earlier time points and higher rates in 3D spheroids expressing oncogenic KRAS compared with wild-type KRAS. In 2D cultures, there was no difference in the rate of apoptosis.

This study shows that high-throughput screening in 3D spheroids can identify potential drugs that would not have been discovered in a 2D format. This provides hope for finding drugs against difficult target proteins such as RAS.

Reference: Kota S., et al. (2018) A novel three-dimensional high-throughput screening approach identifies inducers of a mutant KRAS selective lethal phenotype. Oncogene. Epub ahead of print.

by

Bacteria and Viruses as Cancer Treatments

Over a hundred years ago William B Coley, the “Father of Immunotherapy”, discovered that injection of bacteria or bacterial toxins into tumors could cause those tumors to shrink. The introduction of bacteria had the side-effect of stimulating the immune system to attack the tumor. The field of cancer immunotherapy research—which today includes many different approaches for generating anti-tumor immune responses—originated with these early experiments.

Use of bacteria is one way to stimulate the immune system to attack cancer cells, others include use of cytokines, immune checkpoint blockades and vaccines. This Nature animation provides a simple overview of these methods.

Continue reading →

by

Hello PhD + Promega: Partnering to Support Young Scientists

Hello PhD LogoThink back to your grad school days. Think about a time when you were struggling with challenges either inside or outside the lab. Maybe you dealt with failed experiments, a toxic lab culture or mental health problems. For graduate students, these have been real, everyday experiences for as long as anyone can remember. The Hello PhD podcast, hosted by Joshua Hall and Daniel Arneman, aims to address those problems. We’re excited to announce that beginning with Episode 94 (released June 11, 2018), we are now partnering with Hello PhD to promote their mission to support young scientists in training.

Hello PhD will be celebrating its third anniversary in July 2018, and in the past three years they’ve covered topics from grad school admissions to choosing a career path, and everything in between. They’ve interviewed post-docs, science communicators and students with interesting experiences to share. Their most popular episode ever, “When Research Sucks,” discusses what to do when research starts to drag you down. After 94 episodes, they still haven’t lost sight of their mission to make the grad school experience better for both current and future students. Continue reading →

Factors Influencing Compound Potency in Biochemical and Cellular Assays

Late in 2017, a group here at Promega launched an exciting new assay, the NanoBRET™ Target Engagement (TE) Intracellular Kinase Assay.

It’s easy for me to call this assay exciting; I was an editor on the project team. But judging by the reviews on the SelectScience® web site, others are excited about NanoBRET™ Target Engagement Intracellular Kinase Assay too.

A review of the NanoBRET TE Kinase assay from SelectScience® .

A review of the NanoBRET TE Kinase assay from SelectScience® .

Continue reading →